Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25(4). https://doi.org/10.2807/1560-7917.ES.2020.25.4.2000058.
Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. https://doi.org/10.1001/jama.2020.4344.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
Article
CAS
Google Scholar
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.
Article
CAS
Google Scholar
WHO R&D Blueprint COVID-19. Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis. Geneva: World Health Organization (WHO); 2020. 31st March 2020.
Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101(27):10012–7. https://doi.org/10.1073/pnas.0403596101 Epub 2004 Jun 28.
Article
CAS
PubMed
PubMed Central
Google Scholar
de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–84. https://doi.org/10.1128/AAC.03011-14 Epub 2014 May 19.
Article
CAS
PubMed
PubMed Central
Google Scholar
Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect. 2019;101(1):42–6. https://doi.org/10.1016/j.jhin.2018.09.005 Epub Sep 18.
Article
CAS
PubMed
Google Scholar
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99.
Article
Google Scholar
Dalerba P, Levin B, Thompson JL. A trial of lopinavir-ritonavir in Covid-19. N Engl J Med. 2020;382(21):e68. https://doi.org/10.1056/NEJMc2008043.
Kunz KM. A trial of Lopinavir-ritonavir in Covid-19. N Engl J Med. 2020;382(21):e68. https://doi.org/10.1056/NEJMc2008043.
Corrao S, Natoli G, Cacopardo B. A trial of lopinavir-ritonavir in Covid-19. N Engl J Med. 2020;382(21):e68. https://doi.org/10.1056/NEJMc2008043.
Carmona-Bayonas A, Jimenez-Fonseca P, Castanon E. A trial of lopinavir-ritonavir in Covid-19. N Engl J Med. 2020;382(21):e68. https://doi.org/10.1056/NEJMc2008043.
Havlichek D Jr. A trial of lopinavir-ritonavir in Covid-19. N Engl J Med. 2020;382(21):e68. https://doi.org/10.1056/NEJMc2008043.
WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. https://doi.org/10.1056/NEJMoa2023184.
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–52. https://doi.org/10.1016/S0140-6736(20)32013-4. Epub ahead of print.
Tan D, Walmsley S. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Expert Rev Anti-Infect Ther. 2007;5(1):13–28. https://doi.org/10.1586/14787210.5.1.13.
Article
CAS
PubMed
Google Scholar
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed Feb 17, 2020. 2020.
Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis. 2015;60(Suppl 3):S170–6. https://doi.org/10.1093/cid/civ092.
Article
CAS
PubMed
Google Scholar
Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15(1):F1–9. https://doi.org/10.1097/00002030-200101050-00002.
Article
CAS
PubMed
Google Scholar
Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26):2039–46. https://doi.org/10.1056/NEJMoa012354.
Article
CAS
PubMed
Google Scholar
Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43(2):153–60. https://doi.org/10.1097/01.qai.0000242449.67155.1a.
Article
CAS
PubMed
Google Scholar
Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50(5):474–81. https://doi.org/10.1097/QAI.0b013e31819c2937.
Article
CAS
PubMed
Google Scholar
Leal L, Leon A, Torres B, et al. A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother. 2016;71(7):1982–6. https://doi.org/10.1093/jac/dkw048 Epub 2016 Mar 18.
Article
CAS
PubMed
Google Scholar
Leal L, Leon A, Torres B, et al. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother. 2016;71(7):1987–93. https://doi.org/10.1093/jac/dkw049 Epub 2016 Mar 18.
Article
CAS
PubMed
Google Scholar
Fatkenheuer G, Jessen H, Stoehr A, et al. PEPDar: a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis. HIV Med. 2016;17(6):453–9. https://doi.org/10.1111/hiv.12363 Epub 2016 May 11.
Article
CAS
PubMed
Google Scholar
Corporation A. Product monograph: Kaletra® lopinavir/ritonavir film-coated tablets (100/25 mg, 200/50 mg); 2019.
Google Scholar
U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.
Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505–18. https://doi.org/10.1016/S0140-6736(16)32621-6 Epub 2016 Dec 23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66. https://doi.org/10.1016/S0140-6736(15)61117-5 Epub 2015 Aug 3.
Article
CAS
PubMed
Google Scholar
The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ. 2015;351:h3740. https://doi.org/10.1136/bmj.h3740.
Riley S, Fraser C, Donnelly CA, et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science. 2003;300(5627):1961–6. https://doi.org/10.1126/science.1086478 Epub 2003 May 23.
Article
CAS
PubMed
Google Scholar
Al-Tawfiq JA, Rodriguez-Morales AJ. Super-spreading events and contribution to transmission of MERS, SARS, and SARS-CoV-2 (COVID-19). J Hosp Infect. 2020;105(2):111–12. https://doi.org/10.1016/j.jhin.2020.04.002.
Kretzschmar M, van den Hof S, Wallinga J, van Wijngaarden J. Ring vaccination and smallpox control. Emerg Infect Dis. 2004;10(5):832–41. https://doi.org/10.3201/eid1005.030419.
Article
PubMed
PubMed Central
Google Scholar
Public Health Agency of Canada. Public health management of cases and contacts associated with novel coronavirus disease 2019 (COVID-19). Available at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/interim-guidance-cases-contacts.html#co. Accessed March 18, 2020.
Joint Centre for Bioethics, University of Toronto. Community Tools: Aid to Capacity Evaluation (ACE). Available at: http://www.jcb.utoronto.ca/tools/ace.shtml Accessed February 1, 2021.
Product Monograph. Kaletra lopinavir/ritonavir film-coated tablets (100/25 mg, 200/50 mg). Human immunodeficiency virus (HIV) protease inhibitor. St-Laurent: AbbVie Corporation; 2019.
Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5). https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000062.
Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407–16. https://doi.org/10.1056/NEJMoa1306742 Epub 2013 Jun 19.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jiang X, Rayner S, Luo MH. Does SARS-CoV-2 has a longer incubation period than SARS and MERS? J Med Virol. 2020;13(10):25708.
Google Scholar
Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retrovir. 2007;23(12):1505–14. https://doi.org/10.1089/aid.2007.0107.
Article
CAS
PubMed
Google Scholar
Duthaler U, Berger B, Erb S, et al. Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions. J Antimicrob Chemother. 2018;73(10):2729–37. https://doi.org/10.1093/jac/dky254.
Article
CAS
PubMed
Google Scholar
Kromdijk W, Mulder JW, Smit PM, Ter Heine R, Beijnen JH, Huitema AD. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study. Antivir Ther. 2013;18(6):821–5. https://doi.org/10.3851/IMP2501 Epub 012 Dec 12.
Article
CAS
PubMed
Google Scholar
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. https://doi.org/10.1056/NEJMoa2021436.
Furukawa TA, Kessler RC, Slade T, Andrews G. The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychol Med. 2003;33(2):357–62. https://doi.org/10.1017/s0033291702006700.
Article
CAS
PubMed
Google Scholar
Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32(6):959–76. https://doi.org/10.1017/s0033291702006074.
Article
CAS
PubMed
Google Scholar
Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. 1979;41(3):209–18. https://doi.org/10.1097/00006842-197905000-00004.
Article
CAS
PubMed
Google Scholar
Maunder RG, Lancee WJ, Balderson KE, et al. Long-term psychological and occupational effects of providing hospital healthcare during SARS outbreak. Emerg Infect Dis. 2006;12(12):1924–32. https://doi.org/10.3201/eid1212.060584.
Article
PubMed
PubMed Central
Google Scholar
Pang X, Zhu Z, Xu F, et al. Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003. JAMA. 2003;290(24):3215–21. https://doi.org/10.1001/jama.290.24.3215.
Article
CAS
PubMed
Google Scholar
Goh DL, Lee BW, Chia KS, et al. Secondary household transmission of SARS, Singapore. Emerg Infect Dis. 2004;10(2):232–4. https://doi.org/10.3201/eid1002.030676.
Article
PubMed
PubMed Central
Google Scholar
Personal communication with Dr. Allison McGeer on Feb 14, 2020.
Muller MP, Richardson SE, McGeer A, et al. Early diagnosis of SARS: lessons from the Toronto SARS outbreak. Eur J Clin Microbiol Infect Dis. 2006;25(4):230–7. https://doi.org/10.1007/s10096-006-0127-x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thai PQ, Mai le Q, Welkers MR, et al. Pandemic H1N1 virus transmission and shedding dynamics in index case households of a prospective Vietnamese cohort. J Inf Secur. 2014;68(6):581–90. https://doi.org/10.1016/j.jinf.2014.01.008 Epub Feb 1.
Article
Google Scholar
Petrie JG, Ohmit SE, Cowling BJ, et al. Influenza transmission in a cohort of households with children: 2010-2011. PLoS One. 2013;8(9):e75339. https://doi.org/10.1371/journal.pone.0075339 eCollection 2013.
Article
CAS
PubMed
PubMed Central
Google Scholar
Carcione D, Giele CM, Goggin LS, et al. Secondary attack rate of pandemic influenza A(H1N1) 2009 in Western Australian households, 29 May-7 August 2009. Euro Surveill. 2011;16:3.
Google Scholar
Cauchemez S, Donnelly CA, Reed C, et al. Household transmission of 2009 pandemic influenza a (H1N1) virus in the United States. N Engl J Med. 2009;361(27):2619–27. https://doi.org/10.1056/NEJMoa0905498.
Article
CAS
PubMed
Google Scholar
Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(9):245–6. https://doi.org/10.15585/mmwr.mm6909e1.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;27(20):30287–5.
Google Scholar
Jing QL, Liu MJ, Zhang ZB, Fang LQ, Yuan J, Zhang AR, Dean NE, Luo L, Ma MM, Longini I, Kenah E, Lu Y, Ma Y, Jalali N, Yang ZC, Yang Y. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1141–50. https://doi.org/10.1016/S1473-3099(20)30471-0.
Li W, Zhang B, Lu J, Liu S, Chang Z, Peng C, Liu X, Zhang P, Ling Y, Tao K, Chen J. Characteristics of Household Transmission of COVID-19. Clin Infect Dis. 2020;71(8):1943–46. https://doi.org/10.1093/cid/ciaa450.
Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–25. https://doi.org/10.1056/NEJMoa2016638.
Donner A, Klar N. Pitfalls of and controversies in cluster randomization trials. Am J Public Health. 2004;94(3):416–22. https://doi.org/10.2105/ajph.94.3.416.
Article
PubMed
PubMed Central
Google Scholar
Brown CH, Ten Have TR, Jo B, et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009;30:1–25. https://doi.org/10.1146/annurev.publhealth.031308.100223.
Article
PubMed
PubMed Central
Google Scholar
Larios OE, Coleman BL, Drews SJ, et al. Self-collected mid-turbinate swabs for the detection of respiratory viruses in adults with acute respiratory illnesses. PLoS One. 2011;6(6):e21335. https://doi.org/10.1371/journal.pone.0021335 Epub 2011 Jun 23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Granados A, Quach S, McGeer A, Gubbay JB, Kwong JC. Detecting and quantifying influenza virus with self- versus investigator-collected mid-turbinate nasal swabs. J Med Virol. 2017;89(7):1295–9. https://doi.org/10.1002/jmv.24753 Epub 2017 Feb 27.
Article
PubMed
Google Scholar
WHO R&D Blueprint COVID-19. Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis. Geneva, Switzerland. 10 April 2020.
WHO R&D Blueprint COVID-19. Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis. Geneva, Switzerland. 16 April 2020.
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
Ali M, Han S, Gunst CJ, Lim S, Luinstra K, Smieja M. Throat and nasal swabs for molecular detection of respiratory viruses in acute pharyngitis. Virol J. 2015;12:178. https://doi.org/10.1186/s12985-015-0408-z.
Article
CAS
PubMed
PubMed Central
Google Scholar
Van Wesenbeeck L, Meeuws H, D'Haese D, et al. Sampling variability between two mid-turbinate swabs of the same patient has implications for influenza viral load monitoring. Virol J. 2014;11:233. https://doi.org/10.1186/s12985-014-0233-9.
Article
PubMed
PubMed Central
Google Scholar
Matsuishi K, Kawazoe A, Imai H, et al. Psychological impact of the pandemic (H1N1) 2009 on general hospital workers in Kobe. Psychiatry Clin Neurosci. 2012;66(4):353–60. https://doi.org/10.1111/j.440-819.2012.02336.x.
Article
PubMed
Google Scholar
Wang Y, Xu B, Zhao G, Cao R, He X, Fu S. Is quarantine related to immediate negative psychological consequences during the 2009 H1N1 epidemic? Gen Hosp Psychiatry. 2011;33(1):75–7. https://doi.org/10.1016/j.genhosppsych.2010.11.001 Epub Dec 13.
Article
PubMed
Google Scholar
Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549–56.
Article
CAS
Google Scholar
Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205–211. https://doi.org/10.1038/s41591-021-01230-y.
Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J. Converting the maybes: crucial for a successful COVID-19 vaccination strategy. PLoS One. 2021;16(1):e0245907.
Article
CAS
Google Scholar
Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, Mlisana K, Bhiman JN, von Gottberg A, Walaza S, Fonseca V, Allam M, Ismail A, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Williamson C, Petruccione F, Sigal A, Gazy I, Hardie D, Hsiao NY, Martin D, York D, Goedhals D, San EJ, Giovanetti M, Lourenço J, Alcantara LCJ, de Oliveira T. Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med. 2021. https://doi.org/10.1038/s41591-021-01255-3.
Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang ML, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. Ann Intern Med. 2020;M20–6519. https://doi.org/10.7326/M20-6519. Epub ahead of print.
Mitjà O, Corbacho-Monné M, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. 2021;384(5):417–27.
Article
Google Scholar
Smit M, Marinosci A, Nicoletti GJ, et al. Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial. BMJ Open. 2020;10(11):e040110.
Article
Google Scholar